All patients, BL | CTCBL+ | P | All patients, 1C | CTC1C+ | P | |
---|---|---|---|---|---|---|
Patients | 393 | 133 (34%)* | 201 | 57 (28%) | ||
Age, median (range); years | ||||||
at initial diagnosis | 51 (23–81) | 50 (28–81) | 0.853 | 50 (28–77) | 50 (33–77) | 0.570 |
at study inclusion | 59 (29–89) | 57 (33–81) | 0.030 | 57 (33–89) | 55 (33–77) | 0.092 |
Baseline CTC count, median (range); number/7.5 ml blood | 1 (0–930) | 21 (5–930) | — | — | ||
ER status | 0.631 | 0.729 | ||||
ER+ | 271 | 94 (35%) | 136 | 41 (30%) | ||
ER- | 107 | 34 (32%) | 55 | 15 (27%) | ||
No data | 15 | 5 (33%) | 10 | 1 (10%) | ||
PgR Status | 0.819 | 0.866 | ||||
PgR+ | 240 | 81 (34%) | 124 | 36 (29%) | ||
PgR- | 130 | 46 (35%) | 64 | 20 (31%) | ||
No data | 23 | 6 (26%) | 13 | 1 (8%) | ||
HER2 status of primary tumor | 0.119 | 0.028 | ||||
HER2+ | 67 | 18 (27%) | 30 | 4 (13%) | ||
HER2- | 274 | 102 (37%) | 142 | 49 (35%) | ||
No data | 52 | 13 (25%) | 29 | 4 (14%) | ||
Molecular subtypes | 0.221 | 0.062 | ||||
HR+/HER2- | 216 | 83 (38%) | 110 | 39 (35%) | ||
HER2+ | 67 | 18 (27%) | 30 | 4 (13%) | ||
TNBC | 57 | 19 (33%) | 32 | 10 (31%) | ||
No data | 53 | 13 (25%) | 29 | 4 (14%) | ||
Metastasis site | < 0.001 | 0.005 | ||||
Bone | 68 | 25 (37%) | 40 | 16 (40%) | ||
Visceral/local | 134 | 28 (21%) | 68 | 10 (15%) | ||
Both | 191 | 80 (42%) | 93 | 31 (33%) | ||
No data | 0 | 0 (0%) | 0 | 0 (0%) | ||
Number of metastasis sites | 0.372 | 1.000 | ||||
1 | 88 | 26 (30%) | 48 | 14 (29%) | ||
≥ 2 | 305 | 107 (35%) | 153 | 43 (28%) | ||
No data | 0 | 0 (0%) | 0 | 0 (0%) | ||
Line of therapy | 0.724 | 0.097 | ||||
1 | 175 | 62 (35%) | 97 | 26 (27%) | ||
2 | 81 | 28 (35%) | 44 | 8 (18%) | ||
≥ 3 | 135 | 42 (31%) | 59 | 22 (37%) | ||
No data | 2 | 1 (50%) | 1 | 1 (100%) | ||
Treatments before study | ||||||
Hormonal therapy | 0.904 | 0.167 | ||||
Yes | 289 | 97 (34%) | 143 | 45 (31%) | ||
No | 104 | 36 (35%) | 58 | 12 (21%) | ||
No data | 0 | 0 (0%) | 0 | 0 (0%) | ||
Antibody therapy (bevacizumab or other) | 0.210 | 0.023 | ||||
Yes | 103 | 47 (46%) | 54 | 22 (41%) | ||
No | 288 | 86 (30%) | 146 | 35 (24%) | ||
No data | 2 | 0 (0%) | 1 | 0 (0%) | ||
Anti HER2 therapy (trastuzumab, lapatinib) | 0.012 | 0.027 | ||||
Yes | 81 | 18 (22%) | 37 | 5 (14%) | ||
No | 311 | 115 (37%) | 163 | 52 (32%) | ||
No data | 1 | 0 (0%) | 1 | 0 (0%) | ||
Chemotherapy | 0.022 | 0.054 | ||||
Mono-CHT | 87 | 24 28%) | 39 | 8 (21%) | ||
Poly-CHT | 109 | 35 (32%) | 64 | 18 (28%) | ||
Bevacizumab + CHT | 93 | 44 (49%) | 47 | 21 (45%) | ||
Other CHTs | 41 | 9 (22%) | 22 | 3 (14%) | ||
No CHT | 62 | 21 (34%) | 28 | 7 (25%) | ||
No data | 1 | 0 (0%) | 1 | 0 (0%) | ||
Radiological response after first cycle of chemotherapy | 0.104 | 0.011 | ||||
CR/PR/SD | 162 | 52 (32%) | 99 | 23 (23%) | ||
PD | 93 | 40 (43%) | 55 | 24 (44%) | ||
No data | 138 | 41 (30%) | 47 | 10 (21%) |